US Patent

US8658676 — Clevidipine emulsion formulations containing antimicrobial agents

Formulation · Assigned to Medicines Co · Expires 2031-10-10 · 5y remaining

Vulnerability score 36/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects formulations of clevidipine, specifically an oil-in-water emulsion, that are resistant to microbial growth and stable against impurities.

USPTO Abstract

Pharmaceutical formulations comprising clevidipine in an oil-in-water formulation that is resistant to microbial growth and stable against the formation of impurities.

Drugs covered by this patent

Cleviprex (CLEVIDIPINE) · Chiesi

Patent Metadata

Patent number: US8658676
Jurisdiction: US
Classification: Formulation
Expires: 2031-10-10
Drug substance claim: No
Drug product claim: Yes
Assignee: Medicines Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.